1. A new alternative concept for cost-effective R&D: The MALdynamics/algorithms/digital informatics
2. General dynamics principle for experimental design of all dose-effect analysis and computer simulation
3. MAL-PD/CI approach for biomedical R&D in vitro and in animals
4. Implementation for MAL-PD Econo-Green R&D
5. Digital R&D approach to international FDA drug evaluation, clinical pharmacology, and clinical trial guidance
6. The epothilone story: Experimental success and clinical failure
7. MAL-PD Advocacy: Public hearing, public comments and scientific recommendations
8. Consensus for international FDAs on definitions of “MAL-PD” and “Synergism”
9. Historical, philosophical, and mathematical analysis: Why the MAL-PD approach and the traditional approach are opposite yet complementary
10. Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method
11. Concluding remarks
Appendices
Postscript
Summary
Appendix 1. Example of two drug combination in vitro, design, execution, data analysis and CompuSyn Report printout (A + B)
Appendix 2. Example of three and two drug simultaneous combinations, design, execution, data analysis and CompuSyn Report printout (A + B + C), (A+B), (B+C) and (A+C)
Appendix 3. Example of two drug simultaneous combination in vivo (Nude mice) for: Experimental design, execution, data analysis and CompuSyn Report printout
Appendix 4. Curative Anti-Tumor Properties of Iso-oxazole-Fludelone (KOS-1803) and Fludelone (KOS 1591) Against Xenograft Tumors including multiple- drug-resisting (MDR) Tumors
Appendix 5. Notes and recommendations for MAL-PD drug evaluation in clinical trials
Appendix 6. The mass-action law system, the pattern, and combinatorial analysis. Chou TC, Ph.D. Thesis, Yale University, 1970. [338], pp 69-169
Glossary and Definitions
Research Supports